1 / 18

Prescribing in Disease

Prescribing in Disease. Clive Roberts. Pain Inflammation Infection Fluid retention Heart problems High blood pressure Epilepsy Parkinsonism Asthma / COPD Peptic ulcer disease. Diarrhoea/constipation Depression Anxiety/sleeplessness Psychosis Metabolic /endocrine diseases

silvio
Télécharger la présentation

Prescribing in Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prescribing in Disease Clive Roberts

  2. Pain Inflammation Infection Fluid retention Heart problems High blood pressure Epilepsy Parkinsonism Asthma / COPD Peptic ulcer disease Diarrhoea/constipation Depression Anxiety/sleeplessness Psychosis Metabolic /endocrine diseases Malignant disease Degenerative disease Haematological problems Etc Etc So what are drugs good at treating (or preventing)?

  3. What could happen to this man? • Massive fluid overload • Hepatic encephalopathy • Gross electrolyte abnormality • Renal Failure • GI or other Haemorrhage • Metabolic abnormaility • Exacerbation of liver disease • Infection • Drug accumulation

  4. And so the risks of drug use in decompensated liver disease • Precipitate encephalopathy • CNS effect • Electrolyte effect • GI effect • Worsen metabolic effect/features of hepatic failure • Fluid retention • Sodium retention • Electrolyte abnormality • Hypoglycaemia • Clotting abnormalities

  5. Continued: • Profound pharmacokinetic disturbance leading to drug accumulation and dose related adverse effects • Decreased systemic clearance of lipid soluble drugs • Increased bioavailability of drugs with high extraction ratio • Decreased plasma protein binding • Altered apparent volume of distribution • Associated impairment of renal function • Failure of pro-drugs • Hepatic blood flow reduction • Worsened hepatic state • Hepatotoxic drugs

  6. Some examples from the BNF table • Anticoagulants • Antidepressants, anxiolytics and hypnotics • Anti-psychotics • NSAIDs • Diuretics • Phenytoin, Carbamazepine • Glibenclamide • Opioids • Rifampicin

  7. Co-amoxyclav, clarythromycin, erythromycin, ketoconazole, isoniazid • Chloramphenicol • Clopidogrel • Cyclophosphamide, methotrexate • Lignocaine • ACE inhibitors • Metformin • Verapamil and some dihydropyridine Ca blockers

  8. Statins • Antacids • Theophylline

  9. Other risk situations • Renal disease • The Elderly • Need for many drugs • Allergy • Lung disease • Heart disease • Gastrointestinal disease • Inherited diseases • Blood diseases • Bone disease • Skin disease • Pregnancy

  10. The renal patient • Pharmacokinetic disturbance • Mainly affecting drug clearance • Also protein binding • Increased sensitivity • Poor tolerance of adverse effects • Decreased effectiveness of some drugs

  11. Drugs in the elderly • Multiple indications leads to polypharmacy • Pharmacokinetic disturbance of metabolism, excretion, protein binding and drug distribution • Increased sensitivity to the actions of drugs on CVS, CNS, GIT • Poor tolerance of adverse effect

  12. Other risk situations • Renal disease • The Elderly • Need for many drugs • Allergy • Lung disease • Heart disease • Gastrointestinal disease • Inherited diseases • Blood diseases • Bone disease • Skin disease • Pregnancy

  13. Remember • Every disease represents a potential contra-indication to particular drugs • Prescribing any drug should only follow a decision that potential benefit outweighs potential risk

More Related